Skip to main content

Table 2 Comparisons of gender, age and cancer rates between BAP1 -mutated and non-mutated cohorts

From: BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs

Variable BAP1-mutated N=63* BAP1-non-mutated N=55 p-value OR (95%CI)
Gender     
Male 22 (36.7%) 31 (56.4%)   
Female 38 (63.3%) 24 (43.6%) 0.034 -
Age of follow-up     
Number known 46 42   
Mean age (Std. Err.) 53.2 (2.1) 51.0 (2.3) 0.4851 -
At least 1 cancer     
Yes 40 (63.5%) 5 (9.1%)   17.39
No 23 (36.5%) 50 (90.9%) <0.001 (6.07-49.83)
Malignant mesothelioma     
Yes 13 (21.0%) 0 (0.0%)   
No 49 (79.0%) 55 (100%) <0.001 -
Uveal melanoma     
Yes 11 (17.7%) 0 (0.0%)   
No 51 (82.3%) 55 (100%) 0.001 -
Cutaneous melanoma     
Yes 8 (12.9%) 0 (0.0%)   
No 54 (87.1%) 55 (100%) 0.007§ -
MBAITs**     
Yes 24 (66.7%) 0 (0.0%)   
No 12 (33.3%) 12 (100%) <0.001 -
Lung cancer     
Yes 3 (4.8%) 0 (0.0%)   
No 59 (95.2%) 55 (100%) 0.246§ -
Breast cancer***     
Yes 3 (7.9%) 1 (4.1%)   
No 35 (91.9%) 23 (95.9%) 0.621§ -
Renal cancer     
Yes 2 (3.3%) 0 (0.0%)   
No 60 (96.7%) 55 (100%) 0.497§ -
  1. Abbreviations: OR: Odds Ratio; CI: confidence interval; *: 62 informative, 1 BAP1-mutated patient had cancer of unknown origin, **: calculated only in individuals belonging to present study, ref. 7 and ref. 10, ***: calculated only in women, -: not calculated; NS: non significant; Std. Err.: standard error; §: two-tailed Fisher’s exact test.